Nectrisine is a natural product with a complex structure containing a pentacyclic core, isolated from the plant *Nectris japonica*. It has been shown to exhibit anti-inflammatory and anti-tumor activities. Studies have focused on understanding its biosynthesis and potential therapeutic applications. Nectrisine’s unique structure and biological activity have made it a target of interest for researchers in the fields of natural product chemistry, medicinal chemistry, and pharmacology.'
nectrisine: produced by the fungus, Nectria lucida F-4490; structure given in first source
ID Source | ID |
---|---|
PubMed CID | 122106 |
MeSH ID | M0156943 |
Synonym |
---|
2h-pyrrole-3,4-diol, 3,4-dihydro-2-(hydroxymethyl)-, (2r-(2-alpha,3-beta,4-alpha))- |
2h-pyrrole, 3,4-diol, 3,4-dihydro-2-(hydroxymethyl)-, (3r-(3alpha,4beta,5alpha))- |
wf 4490 |
nectrisine |
fr 900483 |
(2r-(2-alpha,3-beta,4-alpha))-3,4-dihydro-2-(hydroxymethyl)-2h-pyrrole-3,4-diol |
3,4-dihydro-2-(hydroxymethyl)-,[2r-(2.alpha.,3.beta.,4.alpha.)]-2h-pyrrole-3,4-diol |
2h-pyrrole-3,4-diol |
(2r,3r,4s)-2-(hydroxymethyl)-3,4-dihydro-2h-pyrrole-3,4-diol |
2h-pyrrole-3,4-diol, 3,4-dihydro-2-(hydroxymethyl)-, (2r,3r,4r)- |
108692-47-3 |
3,4-dihydroxy-2-(hydroxymethyl)pyrrolidine |
3,4-dihydroxy-5-hydroxymethyl-1-pyrroline |
DTXSID80910830 |
136615-83-3 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (12.50) | 18.7374 |
1990's | 2 (25.00) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 3 (37.50) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.57) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |